



Vaccine Update # 484 – FluMist vaccine launched, Fluad correction, ATAGI bulletin for immunisation providers, CDC statement on measles and travel vaccines, NCIRS RSV webinar, Spleen Australian webinar recording

FluMist® vaccine launched

The WA Influenza Nasal Spray Vaccination program [was launched](#) by the Minister of Health and Minister for Preventative Health on 14th April.

In 2026, WA Health will offer FluMist®, a live-attenuated influenza vaccine (LAIV) delivered as a nasal spray to children aged 2-11 years.

FluMist® is approved by the Therapeutic Goods Administration for use in individuals aged 2-17 years and will also be available to consumers for private purchase for those aged 12-17 years.

The Structured Administration and Supply Arrangement (SASA) for pharmacists has been expanded to include influenza vaccine immunisation in children aged 2-4 years to allow for the administration of FluMist® to eligible cohorts in pharmacies.

Inactivated influenza vaccines (IIV) remain available for children who:

- are not eligible for the nasal spray influenza vaccine
- prefer an injectable vaccine

- have contraindications for receiving a LAIV intranasal vaccine.

For detailed information about administering FluMist®, please refer to the [Australian Immunisation Handbook](#) and the [ATAGI Statement on the administration of seasonal influenza vaccines in 2026](#).

More information also found in the following resources:

- [2026 WA Influenza Nasal Spray Vaccination Program for Children - Fact Sheet for Providers](#)
- [NCIRS Influenza resources](#)

Please refer your patients to the below digital resources:

[Influenza vaccination for children – Information for WA parents and carers](#)

Correction Vaccine Update 482 - Clarification regarding Fluad® age registration

Information in [Vaccine Update 482](#) incorrectly indicated that the influenza vaccine, Fluad® is not licensed for individuals under 65 years of age. **Correction:** Fluad is registered for people aged 50 years and over.

Australian Technical Advisory Group on Immunisation (ATAGI) bulletin for immunisation providers

ATAGI released a [bulletin for immunisation providers](#) on 27 March 2026. Key updates include:

- information about the influenza season
- pertussis vaccination recommendations for adults
- importance of awareness of vaccine administration errors.

Australian Centre for Disease Control statement on travel and measles vaccination

A new report confirms that almost all cases of [measles](#) in Australia are either acquired overseas or related to an overseas acquired case, especially around school holidays. It also identified that over half of total disease notifications were identified in those aged 20-49 years.

This document can be made available in alternative formats on request for a person with disability.

© Department of Health 2025

Copyright to this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.

Please see the [Centre for Disease Control statement on travel and measles vaccination](#) for more information.

National Centre for Immunisation Research and Surveillance (NCIRS) RSV webinar

Respiratory syncytial virus (RSV) affects people across the lifespan, with infants and older adults experiencing the highest risk of severe disease and hospitalisation. New vaccines, prevention products and funded programs are now available in Australia, creating important opportunities to reduce RSV illness and its impact.

In addition to a live Q&A, experts will discuss:

- disease burden, with a focus on older adults
- RSV immunisation products, including data on effectiveness, safety and uptake
- national, state and territory RSV prevention programs
- real-world case studies and tips for discussing RSV vaccination
- practical considerations for implementing RSV immunisation, including co-administration and approaches to minimising errors.

Date: Thursday 23 April 2026

Time: 14.00–15.30 p.m. (AWST)

Location: Online

[Register now](#) to stay informed about the latest evidence and prevention strategies for RSV.

Spleen Australia webinar: Living without a functioning spleen

Spleen Australia hosted a practical, case-based webinar to support immunisation providers and primary care teams caring for patients without a functioning spleen. It highlights gaps in spleen patient recognition and vaccination and focuses on applying Australian guidelines in everyday practice. The webinar [recording](#) is now available to view on demand.

This document can be made available in alternative formats on request for a person with disability.

© Department of Health 2025

Copyright to this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.